COMP <GO>
CGEN vs PLX // OPERATING MARGIN
Compugen Ltd. (NASDAQ) VS. Protalix BioTherapeutics Inc. (NYSE) • 15-METRIC TALLY: CGEN 7
— PLX 2
▲ OPERATING MARGIN LEADER: CGEN
LAST: $1.98 (-2.94%) • MKT CAP: $193.0M
operating-margins
43.10%
LAST: $2.59 (-0.77%) • MKT CAP: $210.3M
operating-margins
-10.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGEN VS. PLX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CGEN | PLX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.30% | 48.80% | +38.50 | CGEN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | -13.00% | +98.00 | CGEN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.2x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 16.24% | -6.48% | +22.72 | CGEN | /fcf-yield <GO> |
| Operating Margin ACTIVE | 43.10% | -10.40% | +53.50 | CGEN | /operating-margins <GO> |
| Net Profit Margin | 48.60% | -12.50% | +61.10 | CGEN | /net-margins <GO> |
| Revenue Growth (YoY) | 161.10% | -1.20% | +162.30 | CGEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 2/9 | +5.00 | CGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.1 | 47.3 | -6.17 | PLX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 4.6x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $193.0M | $210.3M | -$17.3M | PLX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CGEN REV | PLX REV | CGEN GROSS % | PLX GROSS % | CGEN FCF | PLX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $72.8M | $52.7M | 87.3% | 48.8% | $31.3M | -$13.6M |
| FY 2024 | $27.9M | $53.4M | 71.5% | 54.5% | $49.5M | $7.4M |
| FY 2023 | $33.5M | $65.5M | — | — | -$35.9M | -$1.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGEN // BETA —
PLX // BETA —